Díaz-Redondo, Tamara <br/><br/>
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.  [electronic resource] 

 -  Frontiers in oncology  2019 
 - 1178 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>2234-943X 
<br/><br/><label>Standard No.: </label>10.3389/fonc.2019.01178  doi